- BriaCell Therapeutics Corp (BCT) has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share
- The over-allotment option resulted in additional gross proceeds of approximately US$3.7 million
- Net proceeds from the offering will be allocated to fund clinical trials and research and development
- BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer
- BriaCell Therapeutics Corp (BCT) is down 26.25 per cent, trading at C$4.72 per share at 2 pm ET
BriaCell Therapeutics Corp (BCT) has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 per share.
The over-allotment option granted in connection with the company’s recent public offering resulted in additional gross proceeds of approximately US$3.7 million.
Total gross proceeds for the public offering increased to approximately US$28.7 million.
ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering.
Net proceeds from the offering will be allocated to fund clinical trials and research and development and for general working capital and general corporate purposes.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
BriaCell Therapeutics Corp (BCT) is down 26.25 per cent, trading at C$4.72 per share at 2 pm ET.
